PRISM BioLab Co.,LTD

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

35

Website

prismbiolab.com

Country

Japan

Exchange

Tokyo

Founded 2006

PRISM BioLab provides the research and development of pharmaceuticals using its proprietary drug discovery platform technology, PepMetics Technology. It develops E7386 targeting CBP/beta-catenin, which is in Phase II clinical trial for the treatment of cancer

PRI724 targeting CBP/beta-catenin that is in Phase II clinical trial for treating cirrhosis. The company has a strategic collaboration with Receptor.AI Inc. for the development of an AI-integrated drug discovery platform. Founded in 2006, the company is based in Fujisawa, treating Japan.

Key Stats

52-Week Range

¥125.00¥279.00

Beta1.40

Trailing P/EN/A

Forward P/EN/A

Trailing EPS-26.11

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.